Stryker (SYK) Q4 2025 earnings review
Double-Digit Finish Caps Strong 2025, But 2026 Outlook Signals Normalization
Stryker finished 2025 with an acceleration in revenue, delivering 11.0% organic growth in Q4 (up from 9.5% in Q3) and a massive 56% jump in reported EPS. The MedSurg and Neurotechnology segment did the heavy lifting, accelerating to 12.6% organic growth, while Orthopaedics slowed sequentially. Management delivered on profitability promises with a 100 bps expansion in adjusted operating margin to 30.2%. However, the initial 2026 guidance (8.0-9.5% organic growth) implies a deceleration from the double-digit pace set in 2024 and 2025, suggesting a potential normalization of demand or conservatism.
🐂 Bull Case
MedSurg and Neurotechnology organic growth accelerated to 12.6% in Q4 (vs 8.4% in Q3), driven by exceptional strength in Endoscopy (+13.6% US CC) and Medical (+11.3% US CC), indicating a robust capital equipment environment.
Stryker delivered a 100 basis point improvement in Adjusted Operating Margin for both Q4 (30.2%) and the Full Year (26.3%), proving the company can expand profitability even while absorbing acquisition costs.
🐻 Bear Case
Orthopaedics organic growth slowed to 8.4% in Q4 from 11.4% in Q3. Specifically, U.S. Hips (+6.6% CC) and Knees (+7.9% CC) both decelerated sequentially compared to Q3 levels (+8.7% and +8.4% respectively), suggesting potential competitive pressure or market normalization.
After two consecutive years of >10% organic growth (10.2% in 2024, 10.3% in 2025), the FY26 guidance of 8.0-9.5% implies a shift away from the double-digit trend line.
⚖️ Verdict: 🟢
Bullish. While Orthopaedics showed slight cooling, the broader portfolio strength—particularly in capital-heavy MedSurg segments—is undeniable. The company is generating significant cash ($5B operating cash flow) and expanding margins. The FY26 guidance likely reflects prudence rather than structural weakness.
Key Themes
MedSurg & Neurotechnology Powering Growth
This segment has overtaken Orthopaedics as the primary growth accelerator. In Q4, organic sales surged 12.6% (vs 8.4% in Q3). The strength was broad-based in the U.S., with Endoscopy (+13.6% Constant Currency) and Medical (+11.3% CC) showing that hospital capital budgets remain wide open for Stryker's ecosystem.
Margin Expansion Story Intact
Despite headwinds from tariffs and acquisitions mentioned in prior quarters, Stryker hit its target. Q4 Adjusted Operating Margin reached 30.2%, up 100bps YoY. Full-year margin also expanded 100bps to 26.3%. This demonstrates strong pricing power and cost discipline.
Sequential Cooling in U.S. Implant Growth
While still healthy, the core joint replacement business showed signs of deceleration in the U.S. market (Constant Currency). U.S. Knees grew 7.9% in Q4 (down from 8.4% in Q3) and U.S. Hips grew 6.6% (down from 8.7% in Q3). This sequential slowing warrants monitoring to see if it stems from tougher comps, market saturation, or competitive share shifts.
Vascular Segment Expansion
The Vascular sub-segment reported massive 58.1% revenue growth in Q4. This is primarily inorganic, driven by the Inari Medical acquisition (closed Q1 2025). While not fully organic yet, the scale of this revenue jump confirms the successful integration and immediate top-line impact of the portfolio reshaping strategy.
Cash Flow Generation
Operating Cash Flow for FY25 surged to $5.04B, a 19% increase from $4.24B in FY24. This significantly outpaced the 8.5% growth in Net Earnings, indicating high-quality earnings and excellent working capital management (Accounts Receivable remained flat YoY despite 11% sales growth).
Other KPIs
Solid. Crossed the $25B milestone. Growth was 11.2% reported and 10.3% organic, marking the second consecutive year of double-digit organic growth.
Accelerating. Up 11.5% YoY. This growth rate slightly outpaced the organic revenue growth of 11.0%, reflecting the margin expansion mechanics.
Stable. International organic growth was 10.4% (constant currency sales growth), lagging the U.S. growth of 11.7% (constant currency) slightly but remaining in double-digits.
Guidance
Decelerating. The midpoint (8.75%) is below the 10.3% delivered in FY25 and 10.2% in FY24. Management cites "momentum" but sets a bar that implies a return to high-single digits rather than sustaining double digits.
Stable growth. At the midpoint ($15.00), this implies ~10% growth over FY25's $13.63. This aligns with the revenue guide plus modest margin expansion leverage.
Stable. Management expects pricing to remain a tailwind, consistent with the 0.4% positive price impact realized in FY25.
Key Questions
Orthopaedics Deceleration
Organic growth in Orthopaedics slowed to 8.4% in Q4 from 11.4% in Q3, with U.S. Hips and Knees both cooling sequentially. Is this solely due to comp dynamics, or are you seeing any changes in competitive share or procedural volumes?
Guidance Conservatism
Given the 'outstanding finish' to 2025 with 11% organic growth, the 2026 guide of 8.0-9.5% implies a deceleration. What specific headwinds or market normalization assumptions underpin the lower end of that range?
Capital Equipment Visibility
Endoscopy and Medical had exceptional quarters, suggesting a robust capital environment. Does your 2026 outlook assume this elevated level of hospital CapEx persists, or are you modeling a reversion to the mean?
Vascular Organic Performance
Vascular reported growth was 58%, largely due to the Inari acquisition. Can you parse out the underlying organic performance of the legacy Neurovascular/Vascular business versus the pro-forma performance of the acquired assets?